Quick Answer
Cabaletta Bio, Inc. reported Net Income Loss of -$167.86 million for the year ending 2025.
- Cabaletta Bio, Inc. showed a decrease of -44.9% in Net Income Loss from 2024 to 2025.
- This data is from Cabaletta Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$9.28 million | Q1 2019: -$3.53 million | Q2 2019: -$3.36 million | Q3 2019: -$4.65 million | Q1 2020: -$7.49 million | Q2 2020: -$8.15 million | Q3 2020: -$8.39 million | Q1 2021: -$9.70 million | Q2 2021: -$11.14 million | Q3 2021: -$11.56 million | Q1 2022: -$12.95 million | Q2 2022: -$12.91 million | Q3 2022: -$11.43 million | Q1 2023: -$15.85 million | Q2 2023: -$14.49 million | Q3 2023: -$16.45 million | Q1 2024: -$25.05 million | Q2 2024: -$27.60 million | Q3 2024: -$30.63 million | Q1 2025: -$35.94 million | Q2 2025: -$45.13 million | Q3 2025: -$44.87 million.
- Over the full 8 years of available data (2018 to 2025), Cabaletta Bio, Inc.'s Net Income Loss has declined by 1,275.6%.
- Historical annual values: Fiscal year 2025: -$167.86 million | Fiscal year 2024: -$115.86 million | Fiscal year 2023: -$67.68 million | Fiscal year 2022: -$52.98 million | Fiscal year 2021: -$46.29 million | Fiscal year 2020: -$33.34 million | Fiscal year 2019: -$16.94 million | Fiscal year 2018: -$12.20 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: